Table 4

Grade three or four treatment-related non-haematological adverse events by number of patients1
Adverse event Group A2(n=9) Group B3(n=6) Group C4(n=21) Group D5(n=6)
Gd 3 Gd 4 Gd 3 Gd 4 Gd 3 Gd 4 Gd 3 Gd 4
Fatigue 2 - - - 6 - 2 2
Febrile neutropenia - 3 2 - 1 - - -
Alopecia - - - - 3 - - -
Nausea 1 - - - 1 - - -
Respiratory infection - - 1 - - - 1 -
Vomiting - - - - 2 - - -
Anaemia - - - - 1 - - -
Anorexia - - - - 1 - - -
Dehydration - - - - 1 - - -
Diarrhoea - - - - 1 - - -
Leukopenia 1 - - - - - - -
QT/QTc prolongation - - - - - - 1 -
Weight loss - - - - 1 - - -

1Highest toxicity grade by CTCAE version 3.0 for each patient; 2 PR104 + gemcitabine; 3 PR104 + docetaxel 60; 4 PR104 + docetaxel 60 + GCSF; 5 PR104 + docetaxel 75 + GCSF.

McKeage et al.

McKeage et al. BMC Cancer 2012 12:496   doi:10.1186/1471-2407-12-496

Open Data